Investors in the pharma/biotech sector eagerly wait for pipeline
updates as they play an important role in deciding whether or not
to invest in a particular company. Pipelines are of prime
importance as far as pharma/biotech companies are concerned. These
companies spend a significant amount in advancing their
) announced that it has initiated a phase III study on its oncology
candidate, veliparib in patients suffering from human epidermal
growth factor receptor 2 (HER2) negative metastatic or locally
advanced breast cancer, containing BRCA1 (breast cancer gene 1)
and/or BRCA2 (breast cancer gene 2) mutations.
The randomized, double-blind phase III study will compare the
safety and efficacy of veliparib in combination carboplatin and
paclitaxel, two widely used chemotherapies with carboplatin,
paclitaxel plus placebo combination. The study will enroll
approximately 270 breast cancer patients.
The primary efficacy endpoint of the study is progression-free
survival while the secondary endpoints include overall survival,
clinical benefit rate, objective response rate and duration of
Apart from breast cancer, Veliparib is also being evaluated for
several other oncology indications including non-small cell lung
cancer (phase III).
AbbVie-Shire Takeover Status
AbbVie is currently looking to buy UK-based
). A few days back, Shire rejected the third acquisition proposal
from AbbVie. AbbVie's proposal comprised £20.44 in cash and 0.7988
AbbVie share per Shire share held, representing a value of £46.11
per share of Shire. Additionally, the proposal included the
formation of a new listed holding company in the U.S. post
acquisition with a UK tax domicile. We expect investor focus to
remain on further updates on the acquisition proposal.
Both AbbVie and Shire currently carry a Zacks Rank #3 (Hold).
Better-ranked stocks in the health care sector include
Regeneron Pharmaceuticals, Inc.
), each holding a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
REGENERON PHARM (REGN): Free Stock Analysis
ALLERGAN INC (AGN): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.